An exploration of concomitant psychiatric disorders in children with autism spectrum disorder by Lecavalier, Luc et al.
Comprehensive Psychiatry 88 (2019) 57–64
Contents lists available at ScienceDirect
Comprehensive Psychiatry
j ourna l homepage: www.e lsev ie r .com/ locate /comppsychAn exploration of concomitant psychiatric disorders in children with
autism spectrum disorderLuc Lecavalier a,⁎, Courtney E.McCracken b,Michael G. Aman a, Christopher J.McDougle c, James T.McCracken d,
Elaine Tierney e, Tristram Smith f, Cynthia Johnson g, Bryan King h, Benjamin Handen i, Naomi B. Swiezy j,
L. Eugene Arnold a, Karen Bearss k, Benedetto Vitiello l, Lawrence Scahill b
a Ohio State University, Nisonger Center, United States of America
b Emory University School of Medicine, Department of Pediatrics, United States of America
c Lurie Center for Autism, Massachusetts General Hospital, United States of America
d Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at University of California at Los Angeles, United States of America
e Johns Hopkins University School of Medicine, United States of America
f University of Rochester Medical Center, United States of America
g Cleveland Clinic and Learner College of Medicine, United States of America
h University of California, San Francisco, Department of Psychiatry, Benioff Children's Hospitals, United States of America
i University of Pittsburgh School of Medicine, United States of America
j HANDS in Autism Interdisciplinary Training and Resource Center, Indiana University School of Medicine, United States of America
k University of Washington, Department of Psychiatry and Behavioral Sciences, United States of America
l Division of Child and Adolescent Neuro-Psychiatry, University of Turin, Italy⁎ Corresponding author at: Nisonger Center, Ohio State
Hall, 1581 Dodd Drive, Columbus, OH 43210, United State
E-mail addresses: luc.Lecavalier@osumc.edu (L. Lecava
courtney.mccracken@emory.edu (C.E. McCracken), aman.
CMcDougle@partners.org (C.J. McDougle), jmccracken@m
, tierney@kennedykrieger.org (E. Tierney), Tristram_Smith
(T. Smith), johnsoc@ccf.org (C. Johnson), bryan.king@ucsf
handenbl@upmc.edu (B. Handen), nswiezy@iupui.edu (N.
(L. Eugene Arnold), kbearss@u.washington.edu (K. Bearss
lawrence.scahill@emory.edu (L. Scahill).
https://doi.org/10.1016/j.comppsych.2018.10.012
0010-440X/© 2018 Elsevier Inc. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 23 April 2018
Received in revised form 4 October 2018
Accepted 25 October 2018Objective: We explored patterns of concomitant psychiatric disorders in a large sample of treatment-seeking
children and adolescents with autism spectrum disorder (ASD).
Methods: Participants were 658 children with ASD (age 3–17 years; mean = 7.2 years) in one of six federally-
funded multisite randomized clinical trials (RCT) between 1999 and 2014. All children were referred for hyper-
activity or irritability. Study designs varied, but all used the Child and Adolescent Symptom Inventory or Early
Childhood Inventory to assess Attention Deficit Hyperactivity Disorder (ADHD), Oppositional-Defiant Disorder
(ODD), Conduct Disorder (CD), Anxiety Disorders, andMoodDisorders. In addition, severalmeasures in common
were used to assess demographic and clinical characteristics.
Results:Of the 658 children, 73%were Caucasian and 59% had an IQ N70. The rates of concomitant disorders across
studies were: ADHD 81%, ODD 46%, CD 12%, any anxiety disorder 42%, and any mood disorder 8%. Two or more
psychiatric disorders were identified in 66% of the sample. Of those who met criteria for ADHD, 50% also met
criteria for ODD and 46% for any anxiety disorder. Associations between types of concomitant disorders and a
number of demographic and clinical characteristics are presented.
Conclusion: In this well-characterized sample of treatment-seeking children with ASD, rates of concomitant psy-
chiatric disorders were high and the presence of two or more co-occurring disorders was common. Findings
highlight the importance of improving diagnostic practice in ASD and understanding possible mechanisms
of comorbidity.
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Autism spectrum disorder (ASD) is a group of heterogeneous child-
hood onset conditions characterized by social communication deficits,
restricted interests and repetitive behaviors [1]. The estimated world-
wide prevalence ranges from 6 to 14 per 1000 in children with a 4 to
5 fold higher rate in boys than girls [2]. Because ASD has an early
onset and chronic course, many affected individuals require lifelong
care [3]. The core features of ASD can cause substantial impairments
that may be amplified by behavioral and emotional problems [4,5].
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childrenwith ASD and the focus of psychotropicmedication and behav-
ioral intervention in this population [6,7].
Concomitant psychiatric disorders are common in childrenwith ASD
[8–10]. In a sample of 109 children with autism spectrum disorders,
Leyfer et al. [11] reported that 72% of the children (average age =
9 years; 68% IQ N 70) had at least one Diagnostic and Statistical Manual
of Mental Disorders Fourth Edition (DSM-IV) Axis I disorder. The me-
dian number of co-occurring psychiatric disorders was three. Children
in this study were consecutive cases recruited from longitudinal and
neuroimaging studies, unselected for psychiatric problems. Using an ep-
idemiological sample of 10 to 14-year oldswithDSM-IV ASD (N=112),
Simonoff et al. [10] reported a 3-month prevalence of 70% for concomi-
tant psychiatric disorders with 41% having had two or more diagnoses.
Themost commonwere Social Anxiety Disorder (29%), ODD (30%), and
ADHD (28%). Brookman-Frazee et al. [12] reported that 92% of children
with ASD (N = 201; mean age 9 years, range 4–14) receiving publicly
funded mental health services in Southern California met criteria for
another psychiatric disorder. The most frequently reported psychiatric
disorders were ADHD (78%), ODD (58%), and Anxiety disorders (56%).
In contrast, a randomly selected community sample of 986 children
and adolescents with intellectual disability from a Dutch province re-
ported much lower 1-year prevalence rates, with only 41% of those
screening positive for an ASD meeting criteria for any impairing DSM-
IV diagnosis [13]. Therefore, although psychiatric disorders appear com-
mon in youth with ASD, the range and types of disorders common to
this population merits further study. There is also a need to understand
the demographic and clinical characteristics that are associated with
these concomitant disorders.
The high likelihood of a second psychiatric disorder in children with
one disorder is well established [14]. This observation raises questions
about uncertainty of the boundaries between psychiatric diagnoses in
children. The overlap and shared symptomatology across diagnostic
categories is not unique to children and has led to growing interest in
transdiagnostic constructs [15–17].
In this report, we explore rates, patterns, and correlates of concom-
itant psychiatric disorders in a large sample of well-characterized,
treatment-seeking children with ASD who participated in one of six
federally-funded, multisite RCTs. The children in all six studies wereTable 1
Key characteristics of the six multisite RCT.
Study Aim N Age
range
IQ
evaluation
Treatmen
Aman et al. [18] RIS alone vs. RIS + PT 124 4–14 ASB
Leiter
MSEL
Irritability
Bearss et al. [19] PT vs PEP 180 3–6 MSEL Irritability
Handen et al. [20] ATX vs placebo and
PT vs no PT
128 5–14 ASB
MSEL
Hyperacti
RUPP Autism Network [21] RIS vs. Placebo 101 5–17 NR Irritability
RUPP Autism Network [22] MPH vs. Placebo 72 5–17 SIT Hyperacti
Scahill et al. [23] GUAN vs Placebo 62 5–14 ASB
MSEL
Hyperacti
Abbreviations: GUAN= guanfacine; MPH=methylphenidate; RIS = risperidone; PEP = paren
fifth edition [37]; Leiter= Leiter International Performance Scale [38]; MSEL=Mullen Scale of
errant Behavior Checklist-Irritability subscale; HSQ = Home Situation Questionnaire; CGI-I =
tism Spectrum Disorder; CYBOCS-PDD = Children's Yale-Brown Obsessive-Compulsive Scale
Revised; ABC-H = Aberrant Behavior Checklist-hyperactivity subscale; SNAP-IV ADHD = Sw
and Pelham–version IV Hyperactivity/Impulsivity subscale; M =mean.recruited for disruptive behavior such as tantrums, aggression, self-
injury, impulsive behavior or hyperactivity. We expected to find
(a) high rates of concomitant psychiatric disorders, (b) higher rates of
anxiety disorders in children with an IQ ≥ 70, and (c) poorer response
to the study intervention in childrenwithmore concomitant psychiatric
disorders.
2. Methods
2.1. Participants
The sample of 658 children (585 males and 97 females, aged 3–
17 years) with ASD was participants in one of six multisite RCT
[18–23]. Table 1 shows key characteristics of the six studies, including
treatment targets, entry criteria, and key outcomemeasures. All studies
were approved by each site's institutional review board and written in-
formed consent was obtained from parents or legal guardian prior to
data collection. Participants were recruited from a number of sources
across sites and studies, including schools, the internet, the radio, outpa-
tient clinics, and word of mouth.
2.2. Procedure
An experienced multidisciplinary team conducted a pretreatment
evaluation that included medical and developmental histories, as well
as behavioral and diagnostic assessments. The diagnosis of ASD was
based on the current version of the DSM at the time of the study
[24,25]. In addition to clinical assessment, ASD diagnoses were
supported by either the Autism Diagnostic Interview-Revised [26] or the
Autism Diagnostic Observation Schedule [27]. The pretreatment assess-
ment also included parent and clinician ratings (described below). Par-
ticipants had to be healthy, meet study-specific symptom severity
thresholds, and have a minimum mental age (e.g., receptive language
≥ 18 months). All drug studies required participants to be medication-
free at baseline (with the exception of stable anticonvulsant treatment
for seizure disorder). The parent training study [19] permitted children
to be on psychotropic medication if stable with no planned changes for
the duration of the six-month study.t target Outcome
measures
Entry criteria Primary finding
ABC-I
HSQ
CGI-I
ABC-I ≥ 18
CGI-S ≥ 4
RIS + PT N RIS
ABC-I
HSQ-ASD
CGI-I
ABC-I ≥ 15
CGI-S ≥ 4
PT N PEP
vity and Inattention CGI-I
SNAP
HSQ
ABC
SNAP-IV M ≥ 1.5
CGI-S ≥ 4
ATX & PT N placebo
ABC-I
CGI-I
ABC-I ≥ 18
CGI-S ≥ 4
RIS N placebo
vity ABC-H
CGI-I
SNAP-IV ADHD ≥ 27
SNAP-IV H-I ≥ 10
CGI-S ≥ 4
MPH N placebo
vity ABC-H
ADHD Rating Scale
CGI-I
ABC-H ≥ 24
CGI-S ≥ 4
GUAN N placebo
t education; PT= parent training; ASB = Abbreviated Stanford-Binet Intelligence Scales,
Early Learning [39]; NR= not reported; SIT = Slosson Intelligence Test [40]; ABC-I = Ab-
Clinical Global Impression-Improvement; HSQ-ASD= Home situation Questionnaire-Au-
-Modified for Pervasive Developmental Disorders; RBS-R = Repetitive Behavior Scale–
anson, Nolan, and Pelham–version IV ADHD subscale; SNAP-IV H/I = Swanson, Nolan,
Table 2
Demographic and clinical characteristics of children with ASD.
Characteristics
N (%), unless otherwise noted
N= 658
Age (years), mean ± SD 7.2 ± 2.6
Race
Non-Hispanic White 481 (73.1%)
Non-Hispanic Black 65 (9.9%)
Asian 29 (4.4%)
Hispanic/Latino 54 (8.2%)
Other 29 (4.4%)
Maternal education (n= 557)a
High school graduate or less 91 (16.3%)
Some college/trade school or 4 year degree 385 (69.1%)
Graduate or professional school 80 (14.4%)
Not in household 1 (0.2%)
Intelligence quotient (n= 633)b
b70 257 (40.6%)
≥70 376 (59.4%)
CGI-severity (n= 656)c
Moderate (4) 199 (30.3%)
Marked (5) 327 (49.9%)
Severe or extreme (6 or 7) 130 (19.8%)
ABC, mean ± SD
Irritability (n= 656) 22.7 ± 9.1
Social withdrawal (n= 656) 13.6 ± 8.6
Stereotypic behavior (n= 655) 7.6 ± 5.4
Hyperactivity/noncompliance (n= 655) 32.3 ± 9.0
Inappropriate speech (n= 654) 5.9 ± 3.5
CASI ASD total scored, mean ± SD (n= 654) 20.6 ± 7.3
CGI-improvement summarized only for patients receiving active study treatment.
a RUPP [21] did not collect maternal education.
b IQ not available in 25 subjects.
c CGI not available in 2 subjects.
d Summed score across 12 PDD items. Scores range 0–36.
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2.3.1. Early Childhood Inventory (ECI)/Child and Adolescent Symptom
Inventory (CASI)
The pretreatment assessment also included the ECI or CASI to screen
for concomitant psychiatric conditions. These DSM-IV-referenced,
parent-rated scales are designed to screen for child psychiatric disorders
[28–31]. The ECI and CASI are identical except for minor differences
based on age. Here we used the subscales for ADHD (18 items), ODD
(8 items), CD (10 items for ECI and 15 items for CASI), major depressive
disorder and dysthymia (11 items for ECI and 13 items for CASI), and
ASD (12 items). The subscales for anxiety disorders (21 items for ECI
and 20 items for CASI) included social phobia, generalized anxiety,
and separation anxiety. We did not include specific phobia as it only in-
cludes one item. Previous studies have supported the validity of ECI and
CASI subscales in childrenwith ASD [32,33]. Items are rated 0 (never) to
3 (very often) and can be scored in two different ways: symptom
severity (total of scores within diagnostic category) or symptom count
(number of items rated 2 or 3 within category). In the current study,
symptom counts that met or exceeded DSM-IV criteria were used to
define a positive screen for each diagnostic category.
2.3.2. Aberrant Behavior Checklist (ABC)
The ABC is a 58-item parent rating comprised of five subscales: Irri-
tability (tantrums, aggression, and self-injurious behaviors, 15 items);
Social Withdrawal (response to others, initiation of interaction, 16
items); Stereotypy (mannerisms and repetitive movements, 7 items);
Hyperactivity andnoncompliance (16 items); and Inappropriate Speech
(repetitive vocalizations, 4 items) [34]. Each item is rated 0 to 3 with
higher scores indicating greater severity. Kaat et al. [35] provided evi-
dence of validity and normative data for children with ASD.
2.3.3. Clinical Global Impression-Scale
The Clinical Global Impression – Severity (CGI-S) subscale is a 7-point
scale ranging from 1 (normal) to 7 (among the most extremely ill
patients) [36]. By convention, a score of 3 (Mild) was used to describe
a child who met criteria for ASD without associated behavioral
problems. A score of 4 (Moderate) was required for entry in all trials.
Although the pre-treatment CGI-S score was weighted by the specific
treatment target (e.g., irritability, hyperactivity), the evaluating clinician
incorporated all available information to assign the score.
The Clinical Global Impression-Improvement (CGI-I) subscale is also
a 7-point scale designed to measure overall change from baseline.
Scores on the CGI-I range from 1 (Very Much Improved) through 4
(Unchanged) to 7 (Very Much Worse). In all six trials, scores of Much
Improved or VeryMuch Improved defined positive treatment response.
The CGI-I was rated by an independent evaluator, who was blind to
treatment assignment. In this report, we used the CGI-I to classify treat-
ment response at the end of the acute phase. The Handen et al. [20]
study used separate CGIs for Hyperactivity/Inattention and Noncompli-
ance, as this was a study for youth selected for ADHD. We used the CGI
Hyperactivity/Inattention in this report.
2.4. Measures of intellectual functioning
Different tests were used across the studies to measure intellectual
functioning. They included the Stanford-Binet Intelligence Scales: Fifth edi-
tion [37]; Leiter International Performance Scale-Revised [38],Mullen Scales
of Early Learning [39], and Slosson Intelligence Test [40]. Because several dif-
ferent tests were used, children were classified as ≥70 or b70 IQ.
2.5. Statistical methods
Each of the six data sets was examined for missing data across com-
monmeasures.Minor differences in the documentation of demographic
data (e.g., school placement) were resolved by consensus (LL, CMcC)and by collapsing across levels to allow for aggregating data across
studies. Descriptive statistics were calculated for all variables of interest
and included means and standard deviations for continuous measures
or counts andpercentages for categorical data. The association of concom-
itant diagnoses was examined using generalized estimating equations
(GEE)with a binomial distribution and a logit link [41]. The GEE approach
was used to account for the correlation between participants nested
within a study. Resulting association between diagnoses are presented
as adjusted odds ratios with corresponding 95% confidence intervals.
The frequency of concomitant psychiatric disorders was compared
across demographic and clinical subgroups using Chi-square tests. In
analyses with the CGI-I, only children receiving the active treatment were
included (n= 478). When a demographic or clinical variable was ordinal
(e.g., CGI-Severity: Moderate, Marked, Severe), associations with diagnosis
were tested using the Cochran Armitage test for trend. For continuous var-
iables, such as ASD severity score and age, subjects were stratified by the
median value of the sample (e.g., age ≤ 6 years vs N6 years).
Uniform criteria were used to collapse ECI/CASI subscales for analy-
ses. For example, the presence of any anxiety disorder was based on a
positive screen for generalized anxiety, separation anxiety, or social
anxiety. Similarly, the presence of any mood disorder was based on a
positive screen for major depressive disorder or dysthymia. The pres-
ence of any mood or anxiety disorder was classified as internalizing
disorders; and externalizing disorders comprised ADHD, ODD, or CD.
Statistical analyses were performed using SAS v. 9.4. Given the
sample size and number of comparisons, statistical significance was
assessed at the 0.01 level to control for false discovery rate.
3. Results
3.1. Demographics
Table 2 shows demographic and clinical characteristics of children
with ASD and their caregivers. In all, 73.1% of children were non-
Table 3
Rates of diagnosis in each study.
RUPP [21]
(n= 101)
RUPP [22]
(n= 66)
Aman et al. [18]
(n= 124)
Bearss et al. [19]
(n= 177)
Scahill et al. [23]
(n= 62)
Handen et al. [20]
(n= 128)
Total
(n= 658)
ADHD 72
(71.2%)
57
(86.4%)
105
(84.7%)
132
(74.6%)
59
(95.2%)
109
(85.1%)
534
(81.1%)
ADHD combined 44
(43.6%)
40
(60.6%)
79
(63.7%)
72
(40.7%)
34
(54.8%)
54
(42.2%)
323
(49.1%)
ADHD hyperactive 11
(10.9%)
5
(7.6%)
7
(1.1%)
38
(21.5%)
8
(12.9%)
9
(7.0%)
78
(11.9%)
ADHD inattentive 17
(16.8%)
12
(18.2%)
19
(15.3%)
22
(12.4%)
17
(27.4%)
46
(35.9%)
133
(20.2%)
ODD (n= 657) 42
(41.6%)
23
(35.4%)
78
(62.9%)
95
(53.7%)
20
(32.3%)
41
(32.0%)
299
(45.5%)
CD (n= 656) 19
(19.0%)
4
(6.2%)
27
(21.8%)
18
(10.2%)
4
(6.5%)
5
(3.9%)
77
(11.7%)
Any anxiety disorder (n= 657) 34
(33.7%)
30
(46.2%)
54
(43.6%)
71
(40.1%)
28
(45.3%)
58
(45.3%)
275
(41.9%)
Generalized 18
(17.8%)
19
(29.2%)
30 (24.2%) 35
(19.8%)
18
(29.0%)
40
(31.3%)
160
(24.4%)
Social 22
(21.8%)
11
(16.7%)
31
(25.0%)
27
(15.3%)
18
(29.0%)
32
(25.0%)
141
(21.4%)
Separation 9
(8.9%)
10
(15.2%)
21
(16.9%)
22
(12.4%)
10
(15.2%)
7
(5.5%)
74
(11.3%)
Any mood disorder 7
(6.9%)
4
(6.1%)
13
(10.5%)
19
(10.7%)
4
(6.5%)
2
(1.6%)
49
(7.5%)
Major depression 3
(3.0%)
1
(1.5%)
4
(3.2%)
7
(4.0%)
0
(0%)
1
(0.8%)
16
(2.4%)
Dysthymia 7
(6.9%)
4
(6.1%)
11
(8.9%)
19
(10.7%)
4
(6.5%)
1
(0.8%)
46
(7.0%)
Any externalizing disorder 75
(76.3%)
58
(89.2%)
116
(93.6%)
148
(83.6%)
59
(95.2%)
112
(87.5%)
568
(86.5%)
Any internalizing disorder 36
(35.6%)
31
(47.7%)
57
(46.0%)
78
(44.1%)
29
(46.8%)
59
(46.1%)
290
(44.1%)
60 L. Lecavalier et al. / Comprehensive Psychiatry 88 (2019) 57–64Hispanic White and 59.4% had an IQ ≥ 70. Altogether, 83.5% of mothers
had attended some college/trade school.
3.2. Rates and patterns of concomitant disorders
Table 3 shows positive screen rates for all diagnostic categories.With
a few exceptions, rateswere quite consistent across studies. 81.2% of the
total sample met criteria for any type of ADHD, with most children
meeting criteria for the combined subtype (49.1%). Rates for ODD and
any anxiety disorder were 45.5% and 41.9%, respectively. CD and any
mood disorders occurred at 11.7% and 7.5%, respectively. As shown in
Fig. 1, 66.1% of the sample had two or more concomitant psychiatric
disorders. Fig. 2 depicts the diagnostic overlap in a proportional Venn
Diagram for the three most frequently endorsed diagnostic categoriesFig. 1. Number of concomitanof ADHD, ODD, and any anxiety disorder. Among children who met
criteria for ADHD only 28.1% did not meet criteria for ODD or an anxiety
disorder. In the full sample, 24% met criteria for all three diagnostic
categories.
Table 4a presents associations between ADHD and other diagnostic
conditions. It shows significant associations with most categories. All
adjusted odds ratios were above 2.0, with the exception of mood disor-
ders. The odds ratios indicated that the odds of childrenwith ADHD also
having ODD were 2.7 times higher than children without ADHD. Simi-
larly, the odds of having an internalizing disorder were 2.5 times higher
in children with ADHD compared to those without ADHD. The odds of
having CDwere 3 times higher in childrenwith ADHD compared to chil-
dren without ADHD; however the p value = 0.025 and the confidence
interval was quite large.t psychiatric diagnoses.
Fig. 2. Proportional Venn Diagram illustrating patterns of comorbidity.
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diagnostic conditions. All values are statistically significant (p ≤ 0.003)
with adjusted odds ratios N 2.0. Odds of screening positive for an exter-
nalizing disorder were 4.2 times higher in children with an anxiety dis-
order compared to children without an anxiety disorder.
3.3. Demographic and clinical characteristics of participantswith andwith-
out concomitant conditions
Tables 5a and 5b show demographic and clinical characteristics of
children with ASD and at least one additional psychiatric disorder
(note: groups are not mutually exclusive). Table 5a reveals no associa-
tion between the presence of a concomitant disorder and sex. Children
under the age of six years had higher rates of ODD (51.9% vs 41.1%, p=
0.007), but other significant associations with age were not observed.
With the exception of CD andADHD, childrenwith a concomitant disor-
der and thosewith two ormore disorderswere significantlymore com-
mon in children with IQ ≥ 70.
Table 5b shows no association at the p b 0.01 level between diagnos-
tic subtypes and CGI-S. Only one significant association emerged with
CGI-I. Children who responded to study interventions were less likely
to screen positive for ODD (37.6% positive responder vs 51.2% non-Table 4a
Frequency of concomitant psychiatric diagnoses in children with and without ADHDa.
No ADHD
(N= 123)
ADHD
(N= 534)
ODD 33 (26.8%) 266 (49.8%
CD 6 (4.9%) 71 (13.3%)
Anxiety disorder 31 (25.2%) 244 (45.7%
Mood disorder 7 (5.7%) 42 (7.9%)
Internalizing disorder 33 (26.8%) 257 (48.1%
a Percents are percent of the column with the indicated diagnosis.
b Adjusted for correlation of subjects nested within study.responder, p= 0.003). Finally, children with more elevated ASD scores
had higher rates of psychiatric problems in all categories, but only
ADHD and externalizing disorders reached statistical significance at
the p b 0.01 level.
4. Discussion
This is one of the largest studies of concomitant psychiatric disorders
in children with ASD published to date. A unique aspect of the report is
thewell-characterized sample,with longitudinal data on treatment out-
come. The findings suggest that boundaries of co-occurring DSM-
defined disorders are blurry in this sample of childrenwith ASD seeking
treatment for disruptive behavior. The high frequency of multiple DSM-
defined disorders has been reported in several studies of children with
ASD using different methodologies [12,8–10].
The rates and patterns of probable concomitant psychiatric disorders
observed in this sample were similar to those reported in children with
ASD receiving publicly-funded mental health services [12]. The high
rates of ODD and CD in children with ADHD have been observed in
the general pediatric population and in children with ASD [14,10]. In
the current sample of children with ASD, there was also a high co-
occurrence of ADHD and anxiety disorders. Almost half (244 of 534)Adjusted odds ratio (95% CI)b p-Value
) 2.7 (1.66–4.43) b0.001
3.0 (1.15–7.83) 0.025
) 2.5 (1.37–4.55) 0.003
1.4 (0.76–2.69) 0.272
) 2.5 (1.35–4.74) 0.004
Table 4b
Frequency of concomitant psychiatric diagnoses in children with and without an anxiety
disorder.a
No anxiety
disorder
(N= 382)
Anxiety
disorder
(N= 275)
Adjusted odds ratio
(95% CI)b
p-Value
Any ADHD 290 (75.9%) 244 (88.7%) 2.5 (1.37–4.55) 0.003
ODD 144 (37.7%) 155 (56.4%) 2.1 (1.39–3.28) b0.001
CD 28 (7.4%) 49 (17.8%) 2.7 (2.13–3.51) b0.001
Mood disorder 15 (3.9%) 34 (12.4%) 3.5 (2.47–4.82) b0.001
Externalizing
disorder
308 (80.6%) 260 (94.6%) 4.2 (1.86–9.34) b0.001
a Percents are percent of the column with the indicated diagnosis.
b Adjusted for correlation of subjects nested within study.
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prevalence estimates for all anxiety disorders are likely understated be-
cause specific phobia was not included. The high co-occurrence of ADHD
and anxiety disorders in youth with ASD was also observed by
Brookman-Frazee et al. [12]. In the general pediatric population, by con-
trast, the review by Angold et al. [14] reported significantly lower co-
occurrence ofADHDandanxiety disorders compared to the associationbe-
tweenADHDandODD/CD. In their sample of 579 childrenwith ADHD, the
Multimodal Treatment Study of ADHD (MTA) observed a 34% rate of anx-
iety disorders (excluding specific phobia) [42]. This higher co-occurrence
of ADHD and anxiety disorders in our sample of children with ASD com-
pared to the general pediatric population may reflect the difficulties par-
ents have in distinguishing between anxiety symptoms from ADHD
symptoms such as restlessness, distractibility and disruptive behavior
[43]. It may also speak to the shared etiology between disorders [44,45].
In the current sample, the rates of concomitant psychiatric disorders
were higher in children with IQ ≥ 70 than children b IQ 70. This trend
was not observed in studies by Simonoff et al. [10] or Brookman-
Frazee et al. [12]. The difference across IQ groups in our sample is
greatest in anxiety disorders. This is consistent with findings in a prior
study in which CASI anxiety scores were significantly lower in children
with IQ b 70, presumably because the presence of language is a precon-
dition for endorsing several anxiety items [46].
The presence of another psychiatric disorder did not drive the CGI-S
ratings. For example, the rates of ADHDand anxiety disorderswere sim-
ilar across CGI-S ratings of Moderate, Marked or Severe. On the CGI-I,
children with concomitant ODDweremore likely to show a positive re-
sponse. We note that these trials selected children with disruptiveTable 5a
Demographic characteristics of children with ASD by concomitant diagnostic condition.a,b
Co-occurring disorder group Sex Age
Male
(N= 563)
Female
(N= 94)
p-Value ≤6 yea
(N= 2
ADHD 464
(82.3%)
70
(74.5%)
0.073 212
(79.1%
ODD 260
(46.2%)
39
(41.5%)
0.398 139
(51.9%
CD 64
(11.4%)
13
(13.8%)
0.496 35
(13.1%
Any anxiety disorder 237
(42.1%)
38
(40.4%)
0.761 103
(38.4%
Any mood disorder 42
(7.5%)
7
(7.5%)
1.00 23
(8.6%)
Internalizing disorder 249
(44.2%)
41
(43.6%)
0.912 111
(41.4%
Externalizing disorder 492
(87.4%)
76
(80.9%)
0.086 232
(86.6%
≥2 additional disorders * 373
(66.1%)
62
(66.0%)
0.973 180
(67.2%
* p b 0.01.
a Groups are not mutually exclusive.
b Percents are percent of the column with the indicated diagnosis.behavior and ADHD. That higher levels of noncompliant and defiant be-
havior at baseline, the essence of ODD, predicted higher positive
response rates is not surprising given that the study treatmentswere di-
rected at these behaviors and selection criteria would have guaranteed
substantial room for participants to show improvements. The rate of
positive response was not influenced by any other diagnostic category.
The minor difference in the rate of positive response for children with
or without a mood disorder fell below our predetermined significance
level. Even the presence of two or more concomitant disorders did not
reduce the rate of positive response. In the MTA study, Jensen et al.
[47] reported that the presence of multiple concomitant psychiatric dis-
orders did affect outcome. Children with ADHD and multiple comorbid
psychiatric disorders required combined mediation and behavioral in-
tervention to respond optimally.
The results of this study raise fundamental questions about the
meaning of concomitant psychiatric disorders in children with ASD.
The introduction of DSM-III was an important milestone for criteria-
driven categorical diagnosis. It has also sparked extensive debate
whether the co-occurring conditions are separate or somehow etiolog-
ically related. In a condition such as ASD involving many aspects of ev-
eryday life, it may not be surprising that youth with ASD would
exhibit behaviors that fall under various diagnostic categories.Whether
the patterns of co-occurring psychiatric disorders in children with ASD
observed in this study are distinct conditions or variable phenotypic
manifestations of ASD cannot be resolved here. The aim of this study
was to describe the patterns of concomitant disorders in children with
ASD and to evaluate similarities and differences of identified subgroups.
Further work on identifying subgroups of children with ASD using cate-
gorical diagnoses, dimensions of symptom severity or biological
markers could lead to refinements in the psychopharmacological and
behavioral interventions in ASD.
Our findings should be interpreted in light of several limitations. The
children described in this report were participants in RCTs focused on
either hyperactivity or disruptive behavior such as tantrums, aggression
and self-injury. The findings may not apply to all children with ASD. In-
deed, RCTs are often criticized for neglecting external validity in favor of
internal validity [48]. The concern is that over emphasis on internal va-
lidity leads to narrow entry criteria and limited generalizability. Despite
the imposition of relatively strict entry criteria, however, the partici-
pants in these multisite studies appear to resemble the complex cases
seen in clinic. In addition, study participants were enrolled from 11 cit-
ies in the US, which also supports the generalizability of the results.
When this limitation on generalizability is appreciated, such a clinicalIQ
r
68)
N6 years
(N= 390)
p-Value b70
(N= 257)
≥70
(N= 376)
p-Value
)
322
(82.6%)
0.265 203
(79.0%)
311
(82.7%)
0.239
)
160
(41.1%)
0.007* 96
(37.4%)
195
(51.9%)
b0.001*
)
42
(10.8%)
0.366 35
(13.6%)
40
(10.7%)
0.260
)
172
(44.2%)
0.140 82
(31.9%)
188
(50.0%)
b0.001*
26
(6.7%)
0.358 10
(3.9%)
35
(9.3%)
0.009*
)
179
(46.0%)
0.244 85
(33.1%)
197
(52.4%)
b0.001*
)
336
(86.4%)
0.944 212
(82.5%)
336
(89.4%)
0.013*
)
255
(65.4%)
0.636 148
(57.6%)
276
(73.4%)
b0.001*
Table 5b
Clinical characteristics of children with ASD by concomitant condition.a,b
Co-occurring disorder group CGI-severity ASD score CGI-improvement (N= 478)
Moderate
(N= 199)
Marked
(N= 327)
Severe
(N= 129)
p-Valuec ≤20
(N= 333)
N20
(N= 321)
p-Value Non response
(N= 189)
Positive responder
(N= 289)
p-Value
ADHD 161
(80.9%)
262
(80.1%)
109
(83.9%)
0.573 255
(76.6%)
277
(86.3%)
0.001* 157
(83.1%)
232
(80.3%)
0.443
ODD 84
(42.2%)
144
(44.0%)
69
(53.5%)
0.060 146
(43.8%)
153
(47.7%)
0.327 71
(37.6%)
148
(51.2%)
0.003*
CD 20
(10.1%)
33
(10.1%)
24
(18.6%)
0.035 30
(9.0%)
47
(14.7%)
0.025 24
(12.8%)
31
(10.7%)
0.496
Any anxiety disorder 80
(40.2%)
140
(42.8%)
55
(42.6%)
0.619 124
(37.2%)
150
(46.7%)
0.014 80
(42.3%)
120
(41.5%)
0.861
Any mood disorder 20
(10.1%)
24
(7.3%)
5
(3.9%)
0.037 19
(5.7%)
30
(9.4%)
0.077 9
(4.8%)
28
(9.7%)
0.049
Internalizing disorder 84
(42.4%)
149
(45.6%)
57
(44.2%)
0.654 132
(39.6%)
157
(48.9%)
0.017 85
(45.0%)
126
(43.6%)
0.767
Externalizing disorder 173
(86.9%)
277
(84.7%)
116
(89.9%)
0.570 276
(82.9%)
290
(90.3%)
0.005* 165
(87.3%)
252
(87.2%)
0.973
At least 2 additional dx* 127
(63.8%)
217
(66.4%)
89
(68.5%)
0.375 206
(61.9%)
228
(71.0%)
0.013 126
(66.7%)
198
(68.5%)
0.673
* p b 0.01.
a Groups are not mutually exclusive.
b Percents are percent of the column with the indicated diagnosis.
c Test for trend; Treating CGI as an ordinal outcome.
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to is similar.
Another limitation is the high reliance on parents as informants. Pa-
rental biases in reporting may have contributed to the blurring of
boundaries between disorders and enhanced the identification of con-
comitant disorders. There might also be misinterpretation by raters of
core features of ASD as psychiatric symptoms. Relatedly, diagnoses
were based solely on caregiver-completed CASI/ECI symptom count
cutoff scores, which do not include consideration of impairment, differ-
ential diagnosis, or multiple sources of information. Therefore, rates
may differ to estimates of “caseness” based on alternative evaluative
strategies. Finally, our analysis focused on DSM categories. We did not
delve into transdiagnostic approaches or research domain criteria,
both of which warrant further research in children with ASD. Of course,
clinical and research realities necessitate both categorical and dimen-
sional approaches. Categories have dimensions, and dimensions be-
come categories when cutoffs are used.
4.1. Conclusions and clinical implications
These data on treatment-seeking children with ASD show that psy-
chiatric problems often occur in multiples. It is further evidence of het-
erogeneity of clinical presentation in ASD and the need to individualize
treatment based on specific pattern of clinical manifestations. Diagnos-
tic assessments of children with suspected ASD also need to be broad-
based and include careful screening for internalizing disorders given
their substantial presence in ASD. As treatments for the core deficits of
ASD are examined, their effects on co-morbid symptomatology should
also be carefully assessed. Lastly, comprehensive early intervention pro-
grams should be aware of the importance of future psychiatric comor-
bidity, and consider preventative interventions attempting to reduce
the emergence of later psychopathology.
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